End points were measured from baseline to week 52. Values are derived from an analysis of variance for the treatment policy estimand (top part of table) and a mixed-model-for-repeated-measures ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback